PepGen (PEPG) Price-to-Projected Revenue Ratio
PepGen Inc. develops drugs for the treatment of neuromuscular pathologies, demonstrating complete independence from economic cycles. The development strategy relies on finding a strategic ally among industry behemoths. The expected market cap-to-revenue ratio clearly captures market expectations, where the parameter value reaches . However, the high density of scientific research in the RNA sector creates significant competitive risks.
Financial and market metric breakdowns for pepgen.com (PEPG)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
PEPG - Company Profit|Projected Future Earnings PepGen Inc.|PEPG - Market Cap to Earnings|Projected Price to Earnings PepGen|PEPG - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PepGen Inc.|PEPG - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months PepGen|PEPG - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months pepgen.com|PEPG - Earnings per share trend in current year|Earnings growth forecast for next year PepGen Inc.
- sales and revenue data:
Initial company analysis:PEPG (PepGen Corp)
The forward P/S ratio assesses the market value of PepGen Inc. (PEPG) relative to expected sales volume, making it possible to determine the extent of asset overvaluation during periods of revenue stagnation. Analyzing the forward P/S chart for PepGen Inc. (PEPG) helps correlate the multiplier's dynamics with the potential of the EDO platform, where a contraction of the metric amid the success of Phase 2 clinical trials could signal that PepGen Inc. (PEPG) is undervalued prior to its market entry.
Direct competitors
Forward P/S Multiple BIIB (Biogen)|Market Cap to Expected Sales Ratio Neurocrine (NBIX)|RGC - Price-to-Projected Revenue Ratio|AXSM (Axsome Corp) - Market Cap to Projected Revenue|ACAD: Forward P/S Multiple|Forward Price-to-Revenue Multiple xenon-pharma.com|Forward Price-to-Revenue Multiple VKTX|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|DNLI: Future Price to Revenue|Forward P/S Multiple HRMY (Harmony Biosciences)|biohavenpharma.com (BHVN) - Market Cap to Future Revenue Ratio|AMLX - Price-to-Projected Revenue Ratio|Future Price to Revenue TRVI|PRAX: Forward P/S Multiple|Projected Price to Revenue Anavex Life Sciences Corp AVXL|Price-to-Projected Revenue Ratio CeriBell, Inc.|Market Cap to Projected Revenue PRTA (Prothena Corporation)|Forward P/S Multiple ALEC|ANNX - Market Cap to Future Revenue Ratio|Omeros - Forward Price-to-Revenue Multiple|Forward P/S Multiple Neurogene Therapeutics NGNE|ACIU - Price-to-Projected Revenue Ratio|Forward Price to Sales VYGR (voyagertherapeutics.com)|Neumora Therapeutics, Inc. (NMRA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scilex Holding (SCLX)|Price-to-Projected Revenue Ratio Tevogen Bio Holdings, Inc.|Alpha Cognition Corp - Future Price to Revenue|Forward P/S Multiple CGTX|IKT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Cassava Sciences SAVA|ASRT (Assertio Holdings) - Future Price to Revenue|Coya - Forward P/S Multiple|Projected Price to Revenue Vistagen Therapeutics (VTGN)|OVID: Forward P/S Multiple|Market Cap to Future Revenue Ratio acumenpharm.com (ABOS)|Price-to-Projected Revenue Ratio CervoMed|Market Cap to Projected Revenue ATHE (Alterity Therapeutics Ltd)|Forward Price-to-Revenue Multiple CLNN (Clene Inc.)|JUNS (Jupiter Neurosciences, Inc.) - Forward Price to Sales|Forward P/S Multiple RLMD (Relmada Therapeutics)|Market Cap to Expected Sales Ratio annovisbio.com (ANVS)|GRCE - Price-to-Projected Revenue Ratio|AIFF (Firefly Neuroscience, Inc.) - Market Cap to Projected Revenue|KLTO: Forward P/S Multiple|Forward Price-to-Revenue Multiple NeuroSense Therapeutics Ltd.|Forward Price-to-Revenue Multiple RVPH|MetaVia, Inc. (MTVA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio NeurAxis (NRXS)|HSDT: Future Price to Revenue|Forward P/S Multiple PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Market Cap to Future Revenue Ratio|NERV - Price-to-Projected Revenue Ratio|Future Price to Revenue ATHA|ADXN: Forward P/S Multiple|Projected Price to Revenue Alzamend Neuro ALZN|Price-to-Projected Revenue Ratio Cyclerion Therapeutics Inc.|Market Cap to Projected Revenue PTIX (Protagenic)|Forward P/S Multiple KTTA|CRGT - Market Cap to Future Revenue Ratio|Avenue Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple Brainstorm Cell Therapeutics Inc. BCLI|CARA - Price-to-Projected Revenue Ratio|Forward Price to Sales CHRO (Chromocell)|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|Price-to-Projected Revenue Ratio Longboard Pharmaceuticals, Inc.|Marinus Pharmaceuticals Inc - Future Price to Revenue|Forward P/S Multiple NKGN|NRBO - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX (synaptogen.com) - Future Price to Revenue|Trevena - Forward P/S Multiple|Projected Price to Revenue Vigil Neuroscience (VIGL)|WENA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Cerevel Corp (CERE)
